Starpharma deal with Dow out of the bag
Thursday, 20 January, 2005
Starpharma (ASX:SPL) was forced into a trading halt this morning after a report in Melbourne broadsheet The Age revealed that Starpharma's US subsidiary Dendritic Nanotechnologies (DNT) was about to consummate an intellectual property deal with US giant Dow Chemical company.
At time of writing, Starpharma had not yet provided the market with clarification on the deal. It reportedly involves the transfer of approximately 200 of Dow's nanotechnology patents, including patents in the dendrimer field in which Starpharma specialises. Dow was to receive an equity stake in DNT as consideration.
In November, Starpharma reported positive preliminary results from the Phase I clinical trial on its dendrimer-based vaginal microbicide Vivagel.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
